

Reference: FOI.ICB-2324/178

Subject: Primary Care Rebates

I can confirm that the ICB does hold the information requested; please see responses below:

QUESTION	RESPONSE		
<p>Which primary care rebate schemes is your ICB/ Health Board currently signed to?</p> <p>If possible, could you please provide the start and end dates of these contracts</p>	Rebate Product	Start date	End date
	Adcal D3	01/04/2018	Until termination
	BD Viva	Company deems start dates/end dates/term as commercially sensitive	
	Butec	01/04/2021	30/04/2024
	Buvidal	01/07/2021	31/12/2023
	Clenil	01/07/2022	30/06/2024
	Espranor	01/01/2022	31/12/2023
	Fostair NEXThaler	01/07/2022	30/06/2024
	Fostair pMDI	01/07/2022	30/06/2024
	FreeStyle Libre	01/09/2022	31/08/2024
	Gatalin XL	01/12/2022	30/11/2023
	Glucophage	01/07/2022	30/06/2024
	Onglyza	Roll on of prev.	Until termination
	Pipexus	01/11/2019	Until termination
	Prostap	Company deems start dates/end dates/term as commercially sensitive	
Ranexa	01/10/2022	30/09/2024	

	Stexerol	01/10/2018	Until termination
	Strivit	01/04/2021	31/03/2024
	Vizidor & Vizidor Duo	01/01/2022	31/12/2023
	Xaggitin	01/04/2018	Until termination
	Zacco	01/07/2022	30/09/2023
	National DOAC rebate	01/01/2022	31/03/2024

The information provided in this response is accurate as of 10 August 2023 and has been approved for release by Dr Joanne Medhurst, Chief Medical Officer for NHS Bristol, North Somerset and South Gloucestershire ICB.